为您找到相关结果约500个

你是不是要搜索 期刊CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC) 点击跳转

CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line(1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)

CheckMate 459: Health-related quality of life (HRQoL) in a randomized, multicenter phase III study ofnivolumab (NIVO) versus sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advancedhepatocellular carcinoma (aHCC)

Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma(HCC): CheckMate 040 study.

Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh

Phase III Trial of Lenvatinib (LEN) vs Sorafenib (SOR) in First-Line Treatment of Patients (PTS) withUnresectable Hepatocellular Carcinoma (uHCC)

Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) withunresectable hepatocellular carcinoma (uHCC).

Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial

Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellularcarcinoma (aHCC): Results from CheckMate 040.

Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellularcarcinoma (aHCC): Subgroup analyses from CheckMate 040

Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (Pts) with advanced hepatocellularcarcinoma (aHCC): Long-term results from CheckMate 040.

Nivolumab (NIVO) plus ipilimumab (IPI) plus cabozantinib (CABO) combination therapy in patients (pts)with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040

Phase 3 trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectablehepatocellular carcinoma (uHCC)

CheckMate 459: Long-term (minimum follow-up 33.6 months) survival outcomes with nivolumab versus sorafenibas first-line treatment in patients with advanced hepatocellular carcinoma

Nivolumab and sorafenib in hepatocellular carcinoma: lessons from the CheckMate 459 study Comment

Cost-effectiveness of nivolumab versus sorafenib as first-line treatment for advanced hepatocellularcarcinoma

为您找到相关结果约500个

共500条页码: 1/34页15条/页